Should postoperative pancreas cancer carry on the auxiliary treatment _'s treatment

Should postoperative pancreas cancer carry on the auxiliary treatment _'s treatment
U.S.A. R o s w e l l P a r k cancer research institute C h u,etc. has shown through following the medical research of card recently, it is only suitable for tumour being already excised ( R 0 ) completely to treat auxiliarily Pancreas cancer patient,and to operation later residual tumour ( R 1 ) Patient come say,assist fail to respond to any medical treatment. ( A n n S u r g O n c o l 2 0 0 3 , 1 0 : 5 3 9 ) C h u,etc. has summarized several items and assisted the large-scale and prospective or reviewing clinical research treating after excising cancer surgery of pancreas. Tumour seminar of intestines and stomach (G I T S G) Conclusion,it is set by the patients of chemotherapy free jointly not to accept surgery later,survive China location time is high than undergoing an operation simply by patienting of treatment (to 11 month on the 20 month, P =0 . 03 ) ,But the research have disease appear, rest on simply at number too little, choose patient and middle location survive to can believe the intersection of block and a series of problem such as being too big time, so has influenced the credibility of its result. The result of study of Norway reveals, in the next 2 years for surgery, it is accepted that auxiliary treatment patient's tumour has not recured time is longer than the patient not accepting auxiliary treatment, but survival rate had no difference in two groups of patients' 2. It's interesting, treat the intersection of group and 5 year instead half the than control group survival rate (4 to 8) . Study and treat the organization (E O R T C) in European cancer Research conclusion putting survival rate is double until 5 year patient such as cancer such as head such as pancreas after can making to chemotherapy, but it can believe the block is too big, has influenced the dependability of its result. Johns. Hopkin Sri Lankan research of hospital that treat the intersection of group and patient, hit the location and is higher than the control group (1 9 notably in life cycle while being auxiliary in conclusion. It takes 5 months and 1 correctly 3 . 5 months, P =0 . 003 ) ,However, this subject is that non- random retrospect is studied, has influenced the dependability of its conclusion. European pancreas cancer research group (E S P A C - 1) The conclusion was equivocal in the research project middle period of the report in 2001, because if can believe the block regarded as and counted the index with 95, accept hitting the location and is longer than the control group in life cycle of the auxiliary patient of chemotherapy group; However, if count by 2 * 2 factorial methods, then the two do not have statistics difference. An important content is in the conclusion in E S P A C - middle period of 1, are longer than the control group (1 9 notably in patient of chemotherapy group's life cycle. It takes 7 months and 1 correctly 4 . 0 months, P =0 . 0 0 0 5 ) ,There is difference greatly between 0 issues of pancreas cancer patient of R and R and a patient among them, namely life cycle's extension mainly takes place to R 0 patients after chemotherapy, and a patient of R's life cycle is only lengthened slightly. The researcher points out finally, about auxiliary and therapeutic curative effect and clinical meaning after the cancer surgery of pancreas, it await not it is many carry on by centring, prospective, at random, controlled study, in the hope of drawing more authoritative conclusion.
|